Skip to content

Research at St Andrews

OMNIgene.SPUTUM suppresses contaminants whilst maintaining Mycobacterium tuberculosis viability and obviates cold-chain transport

Research output: Contribution to journalArticle

Abstract

Tuberculosis (TB) diagnostics are centralised, requiring long-distance transportation of specimens in most resource-limited settings. We evaluated the ability of OMNIgene.SPUTUM (OM-S) to obviate cold-chain transport of TB specimens.

A two-arm (same-day and after 5 days sample processing) study was conducted to assess contamination rates and Mycobacterium tuberculosis viability in OM-S-treated samples against the standard decontamination procedure (SDP) in Mozambique, using Lowenstein Jensen (LJ) and mycobacterial growth indicator tube (MGIT) culture and molecular bacterial load assay.

270 specimens were processed using OM-S and SDP in same-day and 5-day arms. Contamination was lower in OM-S-treated than SDP-treated cultures: 12% versus 15% and 2% versus 27% in the same-day and 5-day arms, respectively. M. tuberculosis recovery in OM-S-treated LJ cultures was 10% and 56% higher in the same-day and 5-day arms, respectively, than SDP-treated cultures, but lower in MGIT (52% and 28% lower in the same-day and 5-day arms, respectively). M. tuberculosis viable count was 1log estimated CFU·mL−1 lower in 5-day OM-S-treated sputa. OM-S was more effective at liquefying sputum with a shorter sample processing time: 22 min for culture.

OM-S is simple to use and has demonstrated a high potency to suppress contaminants, maintenance of viability at ambient temperatures and higher M. tuberculosis recovery, particularly in the solid LJ cultures. Optimisation of OM-S to achieve higher MGIT culture positivity and shorter time to result will increase its application and utility in the clinical management of TB.
Close

Details

Original languageEnglish
Article number00074-2017
Number of pages8
JournalERJ Open Research
Volume4
DOIs
StatePublished - 16 Feb 2018

    Research areas

  • Diagnostic procedures, Tuberculosis, Tuberculosis and mycobacterial infections

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Mycobacterial load assay

    Gillespie, S. H., Sabiiti, W. & Oravcova, K. 2017 Diagnostic Bacteriology: Methods and Protocols. Bishop-Lilly, K. A. (ed.). New York, NY: Humana Press/Springer, p. 89-105 17 p. (Methods in Molecular Biology; vol. 1616)

    Research output: Chapter in Book/Report/Conference proceedingChapter

  2. Optimising molecular diagnostic capacity for effective control of tuberculosis in high-burden settings

    Sabiiti, W. , Mtafya, B. , Kuchaka, D. , Azam, K. , Viegas, S. , Mdolo, A. , Farmer, E. , Khonga, M. , Evangelopoulos, D. , Honeyborne, I. , Rachow, A. , Heinrich, N. , Ntinginya, N. E. , Bhatt, N. , Davies, G. R. , Jani, I. V. , McHugh, T. D. , Kibiki, G. , Hoelscher, M. , Gillespie, S. H. & 1 others PANBIOME (Pan-African Biomarker Expansion Programme) consortium 1 Aug 2016 In : International Journal of Tuberculosis and Lung Disease. 20, 8, p. 1004-1009

    Research output: Contribution to journalArticle

  3. Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study

    Murphy, M. E., Wills, G. H., Murthy, S., Louw, C., Bateson, A. L. C., Hunt, R. D., McHugh, T. D., Nunn, A. J., Meredith, S. K., Mendel, C. M., Spigelman, M., Crook, A. M., Gillespie, S. H. & REMoxTB Consortium 17 Oct 2018 In : BMC Medicine. 16, 11 p., 189

    Research output: Contribution to journalArticle

  4. Phenotypic changes on Mycobacterium tuberculosis-specific CD4 T cells as surrogate markers for tuberculosis treatment efficacy

    Ahmed, M. I. M. , Ntinginya, N. E. , Kibiki, G. , Mtafya, B. A. , Semvua, H. , Mpagama, S. , Mtabho, C. , Saathoff, E. , Held, K. , Loose, R. , Kroidl, I. , Chachage, M. , Both, U. V. , Haule, A. , Mekota, A-M. , Boeree, M. J. , Gillespie, S. H. , Hoelscher, M. , Heinrich, N. , Geldmacher, C. & 1 others Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) 28 Sep 2018 In : Frontiers in Immunology. 9, 13 p., 2247

    Research output: Contribution to journalArticle

ID: 252066828